© 2018 by ROS Therapeutics

Investor & News

Share Information:

ROS Therapeutics ApS is a privately held company, operating under the CVR number 39507501

 

Stock Information:

Number of shares:  81,565
Nominal value per share:  DKK 1                                                                                     

Share capital:  DKK 81,565  

 

Shareholders holding more than 5% of the shares:

ROS Therapeutics Holding ApS

INNOVATIONS A/S

Rasmus Wilhelmsen

 

Principal Law Firm:

Bach Advokater / Ricki Boye

 

Key dates:

Founded:                                                                        23rd of April, 2018

Most recent capital increase:                                      12th of July, 2018

Most recent Annual General Meeting:                       Not applicable

Financial Calendar year-end:                                       31 December

NEWS

Health Europa Quarterly (issue 07) highlights the advantages and disadvantages of the currently recommended first-line treatment for rheumatoid arthritis and reflects on recent research into a possible alternative: A new targeted-MTX treatment underway for rheumatoid arthritis

A New targeted MTX underway for RA

2018-11-11

ROS Therapeutics today announces the successful closing of a DKK 10.1 mill. seed financing round with participation of founders, advisors, business angels and other private investors.

ROS Therapeutics™ raises DKK 10 million in seed financing round

2018-07-13

ROS Therapeutics™ signs patent license agreement with the Technical University of Denmark (DTU) regarding molecules for the treatment of inflammatory diseases and cancer

ROS Therapeutics™ signs patent license agreement

2018-07-03